We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+11.25%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$23.8B
AUM Growth
+$2.95B
Cap. Flow
+$1.1B
Cap. Flow %
4.63%
Top 10 Hldgs %
44.66%
Holding
165
New
18
Increased
38
Reduced
31
Closed
20

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$3.14B
2
AMZN icon
Amazon
AMZN
+$601M
3
AON icon
Aon
AON
+$226M
4
TMO icon
Thermo Fisher Scientific
TMO
+$145M
5
AZEK
The AZEK Co
AZEK
+$100M

Top Sells

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$816M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$403M
3
EXEL icon
Exelixis
EXEL
+$260M
4
MSFT icon
Microsoft
MSFT
+$234M
5
INTU icon
Intuit
INTU
+$205M

Sector Composition

Rank Sector Weight
1 Healthcare 32.61%
2 Technology 13.02%
3 Financials 8.98%
4 Communication Services 7.2%
5 Industrials 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDPW icon
126
Solid Power Inc Warrant
SLDPW
$10.6M
$152K ﹤0.01%
405,316
– –
COGT icon
127
Cogent Biosciences
COGT
$7.24B
$122K ﹤0.01%
17,000
– –
ALT icon
128
Altimmune
ALT
$599M
$107K ﹤0.01%
27,600
– –
NVAX icon
129
Novavax
NVAX
$1.31B
$101K ﹤0.01%
16,000
– –
DYN icon
130
Dyne Therapeutics
DYN
$4.9B
$95.2K ﹤0.01%
10,000
– –
SNDX icon
131
Syndax Pharmaceuticals
SNDX
$1.82B
$93.7K ﹤0.01%
10,000
– –
FOLD
132
DELISTED
Amicus Therapeutics
FOLD
$91.7K ﹤0.01%
16,000
– –
ARDX icon
133
Ardelyx
ARDX
$997M
$90.2K ﹤0.01%
23,000
– –
THRD
134
DELISTED
Third Harmonic Bio
THRD
$83.4K ﹤0.01%
+15,361
New +$76.6K
BYND icon
135
Beyond Meat
BYND
$277M
$66.3K ﹤0.01%
+19,000
New +$55K
GERN icon
136
Geron
GERN
$949M
$60.6K ﹤0.01%
43,000
– –
ANNA
137
AleAnna Inc
ANNA
$105M
$49.8K ﹤0.01%
78,400
– –
IOVA icon
138
Iovance Biotherapeutics
IOVA
$2.87B
$44.7K ﹤0.01%
26,000
– –
CCCC icon
139
C4 Therapeutics
CCCC
$412M
$40K ﹤0.01%
28,000
– –
CGC
140
Canopy Growth
CGC
$410M
$36.6K ﹤0.01%
30,000
– –
BDSX icon
141
Biodesix
BDSX
$248M
$36.1K ﹤0.01%
6,400
-86,565
-93% -$699K
RVMDW icon
142
Revolution Medicines Inc Warrant
RVMDW
$127M
$32.4K ﹤0.01%
120,085
– –
NVNIW
143
Nvni Group Limited Warrants
NVNIW
$836K
$19.4K ﹤0.01%
375,000
– –
IRWD icon
144
Ironwood Pharmaceuticals
IRWD
$714M
$9.32K ﹤0.01%
13,000
– –
BHVN icon
145
Biohaven
BHVN
$2.21B
– –
-4,813,167
Closed -$116M
BPMC
146
DELISTED
Blueprint Medicines
BPMC
– –
-4,000
Closed -$354K
BYSI icon
147
BeyondSpring
BYSI
$35.8M
– –
-19,000
Closed -$58K
CHE icon
148
Chemed
CHE
$7.22B
– –
-400
Closed -$246K
DFS
149
DELISTED
Discover Financial Services
DFS
– –
-4,780,000
Closed -$816M
ELAN icon
150
Elanco Animal Health
ELAN
$11.1B
– –
-16,000
Closed -$168K
3 4 5
6
7

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Farallon Capital Management held 165 positions worth $23.8B, up 14% from $20.9B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Farallon Capital Management deployed $1.1B of net new capital in Q2 2025, opening 18 new positions and adding to 38 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Exelixis, an estimated $260M trimmed.

  • Farallon Capital Management's largest Q2 2025 buy was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.
  • Farallon Capital Management added most to Aon in Q2 2025, an estimated $226M increase.
  • Farallon Capital Management's biggest Q2 2025 reduction was Exelixis, cutting an estimated $260M.
  • Farallon Capital Management fully exited Discover Financial Services in Q2 2025, selling an estimated $816M.
  • Farallon Capital Management's ten largest holdings make up 45% of its $23.8B portfolio in Q2 2025.
  • Farallon Capital Management opened 18 new positions and closed 20 in Q2 2025.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $23.8B.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.